Notícias

Lead program ABCL635 Phase 2 enrollment complete with data expected in August.

AbCellera Biologics recently reported that its investigational antibody ABCL635 achieved statistically significant Phase 2 results, with a single 600 mg subcutaneous dose reducing both the frequency and severity of moderate-to-severe menopausal hot flashes versus placebo while showing a favorable tolerability profile over four weeks. By pairing these data with improvements in sleep and patient-reported outcomes, ABCL635 positions AbCellera as an emerging player in the large, under-served...

The latest analyst update on AbCellera Biologics reflects a higher Fair Value estimate of US$14.63 compared with the prior figure of US$10.43. This shift aligns with more constructive Street research that follows recent clinical data and new partnership agreements. These developments have prompted several firms to revisit their rating and price target work on the stock. Read on to see how these changing assumptions fit into the broader narrative and how you can track the story from...

Why ABCL635’s Phase 2 data matters for AbCellera Biologics stock AbCellera Biologics (ABCL) has become a focus for many biotech investors after announcing that ABCL635 met primary endpoints in a Phase 2 trial for menopause related hot flashes. The single dose of ABCL635 produced statistically significant reductions in both the frequency and severity of vasomotor symptoms versus placebo and was reported as well tolerated, with additional benefits in sleep and patients’ overall perception of...

AbCellera Biologics (NasdaqGS:ABCL) reports positive top line Phase 2 results for ABCL635, its non hormonal antibody treatment for moderate to severe menopausal vasomotor symptoms. The trial shows clinically significant improvement in vasomotor symptoms from a single dose of ABCL635. ABCL635 represents the first clinical success from AbCellera's internal pipeline and supports its GPCR and ion channel antibody discovery platform. The outcome may influence AbCellera's future plans for internal...

AbCellera Biologics stock has surged year to date, yet the company scores poorly on broad valuation checks and currently screens as expensive on market multiples. After a strong run supported by positive clinical news, investors are weighing whether the recent share price strength already reflects much of the good news. Year to date, AbCellera Biologics has delivered a very large 172.3% return, which puts extra focus on whether the current price offers enough margin for error. The recent...

Companies In The Article Are:BA,INTC,HZO,ABCL and ACHR

AbCellera, Replimune and Airbnb reached fresh highs as strong drug data, new funding and better-than-expected earnings boosted investor confidence.

AbCellera Biologics Inc. (NASDAQ:ABCL) rallied for a third consecutive day on Monday to hit a new three-year high, after its drug candidate for hot flashes in menopausal women achieved strong clinical trial results, sparking long-term rosy growth prospects. In intra-day trading, the stock surged to a record high of $10.01 before trimming gains to end […]

(Bloomberg) -- Biotech company AbCellera Biologics Inc. jumped as much as 41%, giving it a market value of almost $3 billion, after it said a potential remedy for hot flashes was effective in a mid-stage trial.Most Read from BloombergChina Unleashes $28 Trillion Capital Markets to Challenge US in AIIran Shakes Up Security Team After Saying Oman Deal ‘Very Close’Stocks Churn as Oil Advance Boosts Treasury Yields: Markets WrapTrump Amps Up Pressure on Billionaire Sargeant to Exit VenezuelaBehind B

New data show a single dose of AbCellera’s menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes.

AbCellera is looking to turn ABCL635 into its first major internally developed clinical success, with Phase 2 data expected shortly.

AbCellera Biologics Inc (ABCL) advances ABCL-635 with early phase 2 completion and secures over $110 million in new T-cell engager deals, despite a wider net loss and revenue decline.

ABCELLERA BIOLG (ABCL) delivered earnings and revenue surprises of -5.88% and -46.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

AbCellera Biologics (NASDAQ:ABCL) said it expects to report top-line data “very soon” from its Phase I study of ABCL635, an antibody being evaluated for moderate-to-severe vasomotor symptoms, or hot flashes, associated with menopause. President and Chief Executive Officer Dr. Carl Hansen said enrol

Vertex Pharmaceuticals (VRTX) is back in focus after AbCellera Biologics announced a collaboration to develop multispecific T cell engagers targeting autoimmune diseases and other conditions. Under the agreement, Vertex will fund the research and retain commercialization rights. See our latest analysis for Vertex Pharmaceuticals. The latest AbCellera collaboration comes as Vertex Pharmaceuticals' share price has risen 15.87% over the past 90 days and the 5 year total shareholder return sits...

Does AbCellera Biologics Inc. (ABCL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here is how AbCellera Biologics Inc. (ABCL) and Agilon Health (AGL) have performed compared to their sector so far this year.

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the Top 10 Hot Stocks with the Highest Upside Potential. On June 5, AbCellera Biologics Inc. (NASDAQ:ABCL) reported that it has appointed Dr. Victor Sandor, M.D.C.M, to its Board of Directors as an independent director. Dr. Sandor is a medical oncologist with extensive experience in developing companies and […]

Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

AbCellera Biologics Inc. (NASDAQ:ABCL) is among the Best Pharmaceutical Stocks. On June 17, 2026, AbCellera Biologics Inc. (NASDAQ:ABCL) and Jazz Pharmaceuticals entered a preclinical research collaboration, option, and license agreement. The deal is to discover and develop next-generation T-cell multispecific antibodies targeting gastrointestinal cancers and other solid tumors. The companies said the partnership includes $56 million […]

Jazz Pharmaceuticals teams up with AbCellera to discover and develop T-cell-engaging antibodies for GI cancers and other solid tumors.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1% and the actively trad

Jazz Pharmaceuticals (NASDAQ:JAZZ) and AbCellera (NASDAQ:ABCL) have signed a preclinical collaboration, option and licensing agreement focused on the discovery and development of T-cell engaging multispecific antibodies for gastrointestinal cancers and other solid tumors. The partnership combines AbCellera’s antibody discovery capabilities with Jazz’s oncology development expertise as the companies seek to advance new cancer therapies.

AbCellera Biologics (ABCL) has been drawing fresh attention after positive interim Phase 1 data for lead antibody ABCL635 and stronger than expected Q1 revenue growth, as the company continues to expand its focus on proprietary drug development. See our latest analysis for AbCellera Biologics. The recent pullback, with a 1 day share price return down 11.8% to US$5.62 and a 7 day share price return down 8.9%, comes after a strong 90 day share price return of 59.7% and a 1 year total...

AbCellera Biologics (NasdaqGS:ABCL) reported positive Phase 1 results for its lead antibody, ABCL635, targeting menopause-related hot flashes. The company is shifting its model from partner-based antibody discovery toward developing its own proprietary drugs. AbCellera appointed Dr. Victor Sandor, a clinical development leader with experience in multiple regulatory drug approvals, to its Board of Directors. AbCellera has built its business around antibody discovery partnerships, and the...

AbCellera Biologics (NASDAQ:ABCL) is emphasizing its transition from a partner-based antibody discovery business to a proprietary drug development company, Chief Financial Officer Andrew Booth said during a company presentation focused on the biotech’s pipeline and lead clinical program. Booth said

Here is how AbCellera Biologics Inc. (ABCL) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.

Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?

AbCellera Biologics Inc. recently reported past first-quarter 2026 results, with revenue rising to US$8.32 million from US$4.24 million a year earlier, while net loss narrowed slightly to US$43.17 million and the company highlighted interim Phase 1 data for its ABCL635 antibody candidate. The combination of higher revenue, a modest improvement in per-share losses, and early ABCL635 safety and pharmacokinetic data moving the program toward Phase 2 has drawn fresh attention to how AbCellera’s...